Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.
Tumors aberrantly express tumor-associated antigens that can be specifically recognized by T-cells, thereby providing a scientific rationale for the design and clinical testing of immunotherapeutic strategies targeting these antigens. Multiple myeloma is a fatal hematologic malignancy. Here, we review techniques to discover new tumor-associated antigens in multiple myeloma and the latest immunotherapeutic strategies employed in this disease.
Chiriva-Internati
Maurizio
M
Department of Microbiology and Immunology and Division of Hematology/Oncology, Texas Tech University Health Sciences Center and Southwest Cancer Treatment and Research Center, Lubbock, Texas 79430, USA. maurizio.chiriva@ttuhsc.edu
Cobos
Everardo
E
Kast
W Martin
WM
D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D058950:Melanoma-Specific Antigens; D009101:Multiple Myeloma / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D009363:Neoplasm Proteins / Q000276:immunology / Q000378:metabolism
D000951:Antigens, Neoplasm; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins